Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) and Echoparameters of Left Ventricular (LV) Diastolic Dysfunction in Pakistani Population

Mehreen Zahra; Muhammad Ali Raza

doi:10.70749/ijbr.v3i5.1296

Authors

Mehreen Zahra Department of General Medicine, Mayo Hospital Lahore, Pakistan
Muhammad Ali Raza Rawalpindi Medical University, Rawalpindi, Pakistan

DOI:

https://doi.org/10.70749/ijbr.v3i5.1296

Keywords:

MASLD, Left Ventricular Diastolic Dysfunction, Echocardiography, Metabolic Dysfunction, Cardiovascular Risk

Abstract

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is widely recognized as a risk factor for cardiovascular disease, however its relationship with left ventricular (LV) diastolic dysfunction remains underexplored. Objective: To assess the association between MASLD and echocardiographic parameters of LV diastolic dysfunction in the Pakistani population. Methodology: This case-control research was performed in the Department of General Medicine, Mayo Hospital, Lahore, for a duration of six months (from July 06, 2024 to January 05, 2025). Seventy individuals (35 MASLD patients and 35 controls) were recruited by non-probability sequential sampling. MASLD was identified using ultrasonography, while LV diastolic dysfunction was evaluated using echocardiographic metrics, including LAVI, E/e′ ratio, deceleration time, and isovolumetric relaxation time. Clinical and biochemical characteristics of significance were documented. Data were evaluated using SPSS version 25, with statistical significance established at p < 0.05. Results: In comparison to controls, MASLD patients had significantly higher LAVI (36.2 ± 5.4 mL/m² vs. 29.1 ± 4.8 mL/m², p<0.001), prolonged DT (230.5 ± 24.3 ms vs. 198.2 ± 20.1 ms, p<0.001), and an increased E/e′ ratio (10.6 ± 2.1 vs. 8.2 ± 1.7, p<0.001). Even after controlling for confounders, MASLD continued to be an independent predictor of LV diastolic dysfunction (OR: 3.85, 95% CI: 2.21–6.71, p<0.001). Conclusion: MASLD is significantly associated with LV diastolic dysfunction, emphasizing the need for cardiovascular risk assessment in these patients.

Downloads

Download data is not yet available.

References

Younossi ZM, Razavi H, Sherman M, Allen AM, Anstee QM, Cusi K, Friedman SL, Lawitz E, Lazarus JV, Schuppan D, Romero‐Gómez M. Addressing the High and Rising Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction‐Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' Perspective. Alimentary Pharmacology & Therapeutics. 2025. https://doi.org/10.1111/apt.70020.

Yanai H, Adachi H, Hakoshima M, Iida S, Katsuyama H. Metabolic-dysfunction-associated steatotic liver disease—its pathophysiology, association with atherosclerosis and cardiovascular disease, and treatments. International journal of molecular sciences. 2023 Oct 23;24(20):15473.

https://doi.org/10.3390/ijms242015473.

European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). Obesity Facts. 2024 Aug 7;17(4):374-443.

https://doi.org/10.1159/000539371.

Younossi ZM, Kalligeros M, Henry L. Epidemiology of metabolic dysfunction associated steatotic liver disease. Clinical and molecular hepatology. 2024 Aug 19.

https://doi.org/10.3350/cmh.2024.0431.

Sandireddy R, Sakthivel S, Gupta P, Behari J, Tripathi M, Singh BK. Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases. Frontiers in cell and developmental biology. 2024 Jul 16;12:1433857. https://doi.org/10.3389/fcell.2024.1433857.

Byrne CD, Armandi A, Pellegrinelli V, Vidal-Puig A, Bugianesi E. Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment. Nature Reviews Gastroenterology & Hepatology. 2025 Feb 17:1-5. https://doi.org/10.1038/s41575-025-01045-z.

Leite AR, Dias J, Godinho T, Correia-Chaves J, Borges-Canha M, Lourenço IM, Leite-Moreira A, Neves JS. Metabolic Dysfunction-associated Steatotic Liver Disease and Heart Failure with Preserved Ejection Fraction: a bidirectional relationship with clinical and therapeutic implications. Endocrinology Insights. 2024:1-7. https://doi.org/10.1159/000541442

Sandireddy R, Sakthivel S, Gupta P, Behari J, Tripathi M, Singh BK. Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases. Frontiers in cell and developmental biology. 2024 Jul 16;12:1433857. https://doi.org/10.3389/fcell.2024.1433857.

Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024 Apr 1;73(4):691-702.

https://doi.org/10.1136/gutjnl-2023-330595.

Zheng, H., Sechi, L.A., Navarese, E.P. et al. Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review. Cardiovasc Diabetol 23, 346 (2024). https://doi.org/10.1186/s12933-024-02434-5

Yanai H, Adachi H, Hakoshima M, Iida S, Katsuyama H. Metabolic-dysfunction-associated steatotic liver disease—its pathophysiology, association with atherosclerosis and cardiovascular disease, and treatments. International journal of molecular sciences. 2023 Oct 23;24(20):15473.

https://doi.org/10.3390/ijms242015473.

Ugwendum D, Mohamed M, Al-Ajlouni YA, Nso N, Njei B, Al-Ajlouni Y. Association of metabolic dysfunction-associated steatotic liver disease (masld) with an increased risk of congestive heart failure in hospitalized patients with cirrhosis: A propensity score-matched analysis. Cureus. 2024 Jun 15;16(6).

https://doi.org/10.7759/cureus.62441.

Braha A, Timar B, Ivan V, Balica MM, Dăniluc L, Timar R. Novel Biomarkers of Grade I Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Patients with Metabolic-Dysfunction-Associated Steatotic Liver Disease. Journal of Clinical Medicine. 2024 Oct 2;13(19):5901. https://doi.org/10.3390/jcm13195901

Czarnik K, Sablik Z, Borkowska A, Drożdż J, Cypryk K. Concentric remodeling and the metabolic-associated steatotic liver disease in patients with type 1 diabetes: an exploratory study. Acta Diabetologica. 2024 Sep 17:1-1. https://doi.org/10.1007/s00592-024-02365-3.

Mancini GJ, Costello D, Bhargava V, Lew W, Lewinter M, Karliner JS. The isovolumic index: a new noninvasive approach to the assessment of left ventricular function in man. The American journal of cardiology. 1982 Dec 1;50(6):1401-8.

https://doi.org/10.1016/0002-9149(82)90482-9.

Leite AR, Dias J, Godinho T, Correia-Chaves J, Borges-Canha M, Lourenço IM, Leite-Moreira A, Neves JS. Metabolic Dysfunction-associated Steatotic Liver Disease and Heart Failure with Preserved Ejection Fraction: a bidirectional relationship with clinical and therapeutic implications. Endocrinology Insights. 2024:1-7. https://doi.org/10.1159/000541442.

Lazo M, Rubin J, Clark JM, Coresh J, Schneider AL, Ndumele C, Hoogeveen RC, Ballantyne CM, Selvin E. The association of liver enzymes with biomarkers of subclinical myocardial damage and structural heart disease. Journal of hepatology. 2015 Apr 1;62(4):841-7. https://doi.org/10.1016/j.jhep.2014.11.024.